State-of-Art of Cellular Therapy for Acute Leukemia

With recent clinical breakthroughs, immunotherapy has become the fourth pillar of cancer treatment. Particularly, immune cell-based therapies have been envisioned as a promising treatment option with curative potential for leukemia patients. Hence, an increasing number of preclinical and clinical studies focus on various approaches of immune cell-based therapy for treatment of acute leukemia (AL). However, the use of different immune cell lineages and subsets against different types of leukemia and patient disease statuses challenge the interpretation of the clinical applicability and outcome of immune cell-based therapies. This review aims to provide an overview on recent approaches using various immune cell-based therapies against acute B-, T-, and myeloid leukemias. Further, the apparent limitations observed and potential approaches to overcome these limitations are discussed.

Automated summary

Immunotherapy has emerged as the fourth pillar of cancer treatment thanks to recent clinical breakthroughs, with immune cell-based therapies showing promise for potentially curative treatment of leukemia patients. However, the use of different immune cell lineages and subsets against various types of leukemia and patient disease statuses presents challenges in interpreting the clinical applicability and outcomes of these therapies.